Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

RCT (n=4076) found efpeglenatide reduced risk of major adverse CV event vs. placebo (7.0 vs. 9.2%;HR,0.73;95% CI,0.58-0.92;p<0.001 noninferiority; p=0.007 superiority) and risk of reduced renal function/macroalbuminuria (13.0 vs. 18.4%; 0.68; 95% CI, 0.57 to 0.79; p<0.001).

SPS commentary:

Efpeglenatide; is a long-acting exendin 4 (exenatide) analogue and glucagon-like peptide-1 (GLP-1) agonist formulated as a weekly subcutaneous injection. It is currently in phase III clinical trials for the management of type 2 diabetes mellitus, including for prevention of cardiac events in those with high cardiovascular risk.

New England Journal of Medicine